Vistagen Therapeutics Faces Federal Securities Class Action Lawsuit
ByAinvest
Friday, Feb 6, 2026 8:58 am ET1min read
VTGN--
Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. (VTGN) for alleged securities violations. The firm encourages investors who purchased VTGN securities between April 1, 2024, and December 16, 2025, to contact Josh Wilson at 877-247-4292 or 212-983-9330 to discuss their options. The investigation focuses on the company's financial statements and potential misrepresentations made to investors. The deadline to seek the role of lead plaintiff in the federal securities class action is March 16, 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet